A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population
Back to article page
Original Article|Updated:2021-08-27
|
A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population
A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population
Chinese Journal of Integrative Medicine2019年25卷第10期 页码:728-735
Affiliations:
1.Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing (100853), China
2.Department of Geriatric Clinic, Inner Mongolia People's Hospital, Hohhot (010017), China
3.Department of Cardiology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing (210011), China
4.Second Department of Cadre's Ward, the First Affiliated Hospital of Harbin Medical University, Harbin (150001), China
5.Department of Cadre Health Care, Tianjin First Central Hospital, Tianjin (300192), China
6.Department of Cardiovascular Medicine, Chongqing General Hospital, Chongqing (400013), China
7.Department of Geriatrics, Shenyang Red Cross Hospital, Shenyang (110063), China
8.Department of Geriatric Cardiology, Guangzhou First People's Hospital, Guangzhou (510180), China
9.Department of Cardiology, Beijing Geriatric Hospital, Beijing (100095), China
10.the Second Department of Cardiology, the Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin (150009), China
11.Department of Cardiology, Guizhou Province Hospital of Traditional Chinese Medicine, Guiyang (550001), China
12.Department of Cadre's Ward, the First Bethune Hospital of Jilin University, Changchun (130021), China
13.Department of Cadre Health Care, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province (325000), China
14.Medical Department, Shanghai Green Valley Pharmaceutical Co., Ltd., Shanghai (201203), China
15.China Health Promotion Foundation, Beijing (100161), China
Author bio:
Correspondence to: Dr. LI Xiao-ying, Tel: 86-10-66876271, E-mail: xyli301@163.com
Funds:
Science and Technology Commission of Shanghai Municipality(15DZ1900300)
Hua CUI, Xiao-ying LI, Xue-wen GAO, 等. A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population[J]. Chinese Journal of Integrative Medicine, 2019,25(10):728-735.
Hua CUI, Xiao-ying LI, Xue-wen GAO, et al. A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population[J]. Chinese Journal of Integrative Medicine, 2019,25(10):728-735.
Hua CUI, Xiao-ying LI, Xue-wen GAO, 等. A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population[J]. Chinese Journal of Integrative Medicine, 2019,25(10):728-735. DOI: 10.1007/s11655-019-2710-x.
Hua CUI, Xiao-ying LI, Xue-wen GAO, et al. A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population[J]. Chinese Journal of Integrative Medicine, 2019,25(10):728-735. DOI: 10.1007/s11655-019-2710-x.
A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population
摘要
Abstract
Objective:
2
To evaluate the efficacy and safety of salvianolate in elderly patients with unstable angina pectoris (UAP).
Methods:
2
A prospective double-blind randomized placebo-controlled multicenter trial in elderly patients with UAP from 13 third-grade class-A hospitals in China was performed. A total of 318 patients were randomly allocated in a 1:1 ratio to an experimental group (160 patients) and a control group (158 patients). The experimental group was treated with salvianolate for 14 days on the basis of conventional medicine
and the control group was given a placebo for 14 days with the same criteria. Follow-up was lasted 28 days in both groups. The primary endpoint was biweekly frequency of angina pectoris attacks. The secondary endpoints included biweekly dosage of nitroglycerin
the Seattle Angina Questionnaire
angina pectoris severity and duration
myocardial injury markers
high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP)
as well as major adverse cardiovascular events (MACEs). Safety was assessed according to adverse events and serious adverse events.
Results:
2
Baseline characteristics were similar between treatment groups. Compared with those in the control group
the frequency of biweekly angina attacks (2.92 vs . 4.08
P
=0.025)
the biweekly dosage of nitroglycerin
as well as the severity and duration of angina attacks (
P
<
0.01) were reduced by salvianolate. The Seattle Angina Questionnaire score was also significantly improved in the experimental group than in the control group (
P
<
0.05). No significant differences were observed between the two groups with respect to the incidence of MACEs. Salvianolate was well tolerated.
Conclusions:
2
Salvianolate appear to have efficacy and well tolerated for elderly patients with UAP. [ClinicalTrials.gov identifier: NCT03037047]
Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia
Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study
Indian Traditional Treatments for Psoriasis: A Critical Appraisal of Available Evidence Supporting Efficacy
Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes: A Randomized, Double-Blind,Placebo-Controlled Multicenter Clinical Study
Usage of Chinese Herbs in Cancer Patients in Southern China: A Survey
相关作者
暂无数据
相关机构
Graduate School, China Academy of Chinese Medical Sciences
Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences
Department of Encephalopathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences
Xiyuan Clinical Medical College, Beijing University of Chinese Medicine
First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine